The Biological Computing Co. Raises $25M
The Biological Computing Co. (TBC) has raised $25 million in seed funding to advance its AI-native biological computing platforms. The company also announced the opening of a new flagship laboratory in San Francisco. The investment signals continued venture capital interest in startups combining artificial intelligence with biological research and development.
- The company was founded by neurosurgeon-scientists Alex Ksendsovsky, MD, PhD, and Jon Pomeraniec, MD, MBA, and was formerly known as Biological Black Box (BBB). The seed round was led by Primary Ventures. - TBC's core technology involves integrating living neurons with silicon-based systems to enhance the performance of AI models for applications like computer vision and generative video. Their platform encodes data into living neurons, then decodes the neural activity into complex mathematical models that serve as a processing layer for existing AI architectures. - The company utilizes small dishes, about the size of a coarse salt grain, containing approximately 100,000 neurons and 4,096 electrodes to stimulate and record neural activity. This approach aims to create AI models that are more stable, scalable, and significantly more energy-efficient than current silicon-only systems. - TBC claims its software "adapters," which are less than 1% of the size of the AI models they augment, can double the length of video an AI can generate before degradation without requiring costly retraining. - The new flagship lab in San Francisco's Mission Bay is intended to support customer deployments, signaling a move towards commercialization of their biological computing platform. - This advancement is part of a broader trend in biocomputing, where companies like Cortical Labs are also developing neuron-on-a-chip systems to tackle complex computational problems and reduce the high energy consumption of traditional AI model training. - The funding reflects a growing venture capital interest in the intersection of AI and biology, even as the broader biotech funding landscape sees shifts. AI is increasingly viewed as a critical enabler for optimizing bioprocesses, including viral vector engineering and manufacturing for gene therapies. - Competitors and adjacent technologies in the AI hardware space include established players like IBM, which is developing brain-inspired architectures, and startups like Groq, which focuses on low-power, AI-specific chips.
